You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
騰盛博藥及開拓藥業跌逾8% 惟來凱醫藥回升12%
內地醫藥生物及疫苗生物板塊齊跌3.5%。本港醫藥股今天普遍跌逾1%-8%,騰盛博藥-B(02137.HK)沽壓最大,股價續跌8.7%報1.67元。開拓藥業-B(09939.HK)報1.27元,回吐8.6%。 凱萊英(06821.HK)、康希諾生物(06185.HK)、寧傑瑞製藥-B(09966.HK)、雲頂新耀-B(01952.HK)、藍籌中生製藥(01177.HK)、藥明康德(02359.HK)及石藥(01093.HK)跌逾2%-3.5%。 然而,來凱醫藥-B(02105.HK)股價曾高見4.55元,現報4.07元,回升12%,成交增至1,211萬股。三葉草生物-B(02197.HK)現報0.5元,續升8.7%。 百濟神州(06160.HK)去年虧損大幅收窄56%,獲大行維持正面評級,該股隨其ADR續升逾半成,股價曾高見108.9元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account